Adjuvant therapy with gefitinib led to significantly longer disease-free survival in patients with completely resected stage II–IIIA NSCLC with EGFR mutations (exon 19del and exon 21 L858R) than platinum-based chemotherapy (25). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.